ERBB2 and cancer: The findings in this study demonstrated a disease-specific survival benefit for statin users who were ER positive (HR 0.69, p=.0.023).This is appreciated in the ER+ invasive cancers (HR 0.70, p=0.024) and ER+ HER2- invasive cancers (HR 0.68, p=0.036), and is a reflection of the risk reduction benefit of statins on cancer recurrence in these ER+ invasive cancers.